ReviewAdvanced pharmaceutical bulletin2020
Pharmaceutical Co-Crystallization: Regulatory Aspects, Design, Characterization, and Applications.
Review in Advanced pharmaceutical bulletin, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 105 citations in OpenAlex.
- Beyond Tuberculosis: Unlocking the Antifungal Potential of Novel Isoniazid Derivatives against Non-ACS omega · 2026Article
- An integrated workflow for the structure elucidation of nanocrystalline powders.Communications chemistry · 2026Article
- ML-Driven Pharmaceutical Cocrystal Technology: Advances in Screening, Property Prediction and Applications.AAPS PharmSciTech · 2026Review
- Nano-cocrystals as Nanotechnology-based Approach to Modulate Solubility and Bioavailability of Poorly Soluble Drugs.Current topics in medicinal chemistry · 2026Review
- Recent Techniques to Improve Amorphous Dispersion Performance with Quality Design, Physicochemical Monitoring, Molecular Simulation, and Machine Learning.Pharmaceutics · 2025Review
- Deep Supramolecular Language Processing for Co-Crystal Prediction.Angewandte Chemie (International ed. in English) · 2025Article
- Review
- Innovative Strategies and Advances in Drug Delivery Systems to Address Poor Solubility: A Comprehensive Review.Current drug targets · 2025Review
- Modification of biopharmaceutical parameters of flavonoids: a review.Frontiers in chemistry · 2025Review
- Improving the Solubility and Bioavailability of Progesterone Cocrystals with Selected Carboxylic Acids.Pharmaceutics · 2024Article
- Enhancing the Stability, Solubility, and Antioxidant Activity of Cinchonine through Pharmaceutical Cocrystallization.Pharmaceutical research · 2024Article
- MOFs for next-generation cancer therapeutics through a biophysical approach-a review.Frontiers in bioengineering and biotechnology · 2024Review
- Sugars and Polyols of Natural Origin as Carriers for Solubility and Dissolution Enhancement.Pharmaceutics · 2023Review
- Synthesis, Characterization, Theoretical and Experimental Anticancer Evaluation of Novel Cocrystals of 5-Fluorouracil and Schiff Bases against SW480 Colorectal Carcinoma.Pharmaceutics · 2023Article
- Amorphization of Ethenzamide and Ethenzamide Cocrystals-A Case Study of Single and Binary Systems Forming Low-Melting Eutectic Phases Loaded on/in Silica Gel.Pharmaceutics · 2023Article
- Cocrystal of phloretin with isoniazid: preparation, characterization, and evaluation.RSC advances · 2023Article
- Overcoming the Drawbacks of Sulpiride by Means of New Crystal Forms.Pharmaceutics · 2022Article
- Article
- Co-Crystals of Resveratrol and Polydatin with L-Proline: Crystal Structures, Dissolution Properties, and In Vitro Cytotoxicities.Molecules (Basel, Switzerland) · 2021Article
- Challenges and opportunities of pharmaceutical cocrystals: a focused review on non-steroidal anti-inflammatory drugs.RSC medicinal chemistry · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmaceutical co-crystals are novel class of pharmaceutical substances, which possess an apparent probability of advancement of polished physical properties offering stable and patentable solid forms. These multi-component crystalline forms influence pertinent physicochemical parameters like solubility, dissolution rate, chemical stability, physical stability, etc. which in turn result in the materials with superior properties to those of the free drug. Co-crystallization is a process by which the molecular interactions can be altered to optimize the drug properties. Co-crystals comprise a multicomponent system of active pharmaceutical ingredient (API) with a stoichiometric amount of a pharmaceutically acceptable coformer incorporated in the crystal lattice. By manufacturing pharmaceutical co-crystals, the physicochemical properties of a drug can be improved thus multicomponent crystalline materials have received renewed interest in the current scenario due to the easy administration in the pharmaceutical industry. There is an immense amount of literature available on co-crystals. However, there is a lack of an exhaustive review on a selection of coformers and regulations on co-crystals. The review has made an attempt to bridge this gap. The review also describes the methods used to prepare co-crystals with their characterization. Brief description on the pharmaceutical applications of co-crystals has also been incorporated here. Efforts are made to include reported works on co-crystals, which further help to understand the concept of co-crystals in depth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.